“Cadmium monitoring at the workplace: effectiveness of a combination of air-and biomonitoring” Lombaert N, Gilles M and Verougstraete V (2023)
Toxics 11(4), 354;
download link: https://doi.org/10.3390/toxics11040354
Continue readingICdA position on setting an occupational exposure limit value in air (OEL) together with a biologic limit value (BLV) for cadmium in urine.
ICdA position on the inclusion of cadmium biomonitoring at the workplace, and on the RAC recommendation for an OEL and BLV.
In its RAC recommendations for OEL and BLV values, RAC did not respond to the Commission request. Indeed, in its latest opinion, the RAC recommended the setting of a BLV without reassessing the OEL originally set at 0.001 mg/m3 (inhalable fraction), a value which was derived precisely under the assumption that no biomonitoring was conducted at the workplace and no BLV was set.
Continue readingCd and Cd compounds not on the draft 11th recommendation list for authorisation
We had informed you that the Draft 11th recommendation list of Substances Subject to Authorisation (Annex XIV) would be discussed in December 2021 at the Member State Committee (MSC-76), and based on ECHA’s priority scoring table, had carefully anticipated that cadmium (and Cd compounds) would not be on the 11th priority list.
Opinion on scientific evaluation of occupational exposure limits for Cadmium and its inorganic compounds
Opinion published by the Committee for Risk Assessment RAC / ECHA/RAC/A77-O-0000006982-64-01/F on 18 March 2021
ICdA submitted comments to the ECHA Call for Evidence: Occupational Exposure Limit for Cd and its Inorganic Compounds
In response to the Call for Evidence, the International Cadmium Association submitted recently updated and extensive information on uses and occupational exposure to cadmium and cadmium compounds collated from measured data by Industry over the last 10 years in the EU, as well as an update summary and conclusions on health effects, toxicology, epidemiology and modes of action from the scientific literature.
The input is structured in 3 parts:
Part 1. Uses and occupational exposure
Part 2. Health effects: Genotoxicity and modes of action
Part 3. Health effects: Repeated dose toxicity and Carcinogenicity
Management of the risks related to Chronic Occupational Exposure to Cadmium and its compounds (2018.2 revision)
The ICdA Guidance to address workplace exposure to cadmium
ICdA announces his revised guidance (2018) on Management of the Risks Related to Chronic Occupational Exposure to Cadmium and its Compounds
The purpose of this document is to supply guidance to occupational medical doctors and managment of plants in which cadmium and hazardous cadmium compounds are being processed, manufactured, transformed, incorporated into articles or recycled, with the purpose of bringing Cd exposure of employees down, resulting in an urinary cadmium level below 2µg Cd/g creatinine.
